Fosamax and the management of osteoporosis
Fosamax, known generically as Alendronate Sodium, is one of the most studied and widely prescribed medications in the bisphosphonate class, a group of antiresorptive agents that have transformed the prevention and treatment of osteoporosis over the past three decades. Since its introduction into clinical practice, Fosamax has helped millions of postmenopausal women and men preserve bone mineral density, reduce fracture risk, and maintain mobility and independence into advanced age. The development of bisphosphonate therapy represented a significant advance for metabolic bone diseases, providing a pharmacological tool to address the fundamental imbalance between bone resorption and bone formation that underlies osteoporotic bone loss. Understanding Fosamax requires an appreciation of bone biology, the pathophysiology of osteoporosis, and the clinical evidence that supports the use of this medication across a range of clinical scenarios.
Osteoporosis, characterized by low bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone fragility and increased fracture risk, is a major public health challenge worldwide. The condition affects approximately one in three postmenopausal women and one in five men over the age of fifty, with the incidence of osteoporotic fractures increasing exponentially with advancing age. Hip fractures, the most devastating consequence of osteoporosis, carry an one-year mortality rate of approximately twenty percent and leave many survivors with permanent disability and loss of independence. Vertebral fractures, though often clinically silent, cause progressive kyphosis, height loss, chronic pain, and reduced quality of life. The silent nature of bone loss until a fracture occurs shows the importance of early identification, risk factor assessment, and appropriate pharmacological intervention, with Fosamax occupying a central role in the therapeutic options.
Pharmacology of alendronate: mechanism of action
Alendronate Sodium belongs to the nitrogen-containing bisphosphonate subclass, which also includes risedronate, ibandronate, and zoledronic acid. These agents involve a nitrogen atom in their side chain that confers potent antiresorptive activity through a specific molecular mechanism distinct from that of the earlier, non-nitrogen-containing bisphosphonates. The bisphosphonate backbone, comprising two phosphonate groups linked by a carbon atom, mimics the structure of endogenous pyrophosphate and has a high affinity for hydroxyapatite crystals, the mineral component of bone. Following oral administration, Alendronate is rapidly cleared from the circulation, with approximately fifty percent of the absorbed dose binding to bone mineral surfaces and the remainder being excreted unchanged in the urine. The drug accumulates preferentially at sites of active bone remodeling, where osteoclast-mediated bone resorption exposes the hydroxyapatite matrix.
When osteoclasts attempt to resorb bone containing Alendronate, they internalize the drug, and within the acidic environment of the osteoclast’s resorption lacuna, the bisphosphonate is released from the bone mineral. Once inside the osteoclast, Alendronate inhibits farnesyl pyrophosphate synthase, a critical enzyme in the mevalonate pathway responsible for the synthesis of isoprenoid lipids required for the prenylation of small GTPase signaling proteins such as Ras, Rho, and Rac. The failure of protein prenylation disrupts the cytoskeletal organization of the osteoclast, interferes with the formation of the ruffled border that characterizes the resorbing osteoclast, and ultimately triggers osteoclast apoptosis. The net result is a reduction in the number and activity of osteoclasts, decreased bone resorption, and a shift in the balance of bone remodeling toward net bone formation, leading to gains in bone mineral density and improved bone strength.
The pharmacokinetics of Alendronate involve low and variable oral bioavailability, which is further reduced by the presence of food, beverages other than plain water, and certain medications including calcium supplements and antacids. For this reason, Fosamax must be taken on an empty stomach with plain water only, at least thirty minutes before the first food, beverage, or other medication of the day. Failure to adhere to these administration requirements can result in negligible drug absorption and loss of therapeutic efficacy. Once absorbed, Alendronate is distributed rapidly to bone or excreted by the kidneys, with minimal metabolism. The drug has a prolonged terminal half-life in bone, estimated at more than ten years, reflecting slow release of Alendronate from the hydroxyapatite matrix as bone undergoes remodeling. This extended skeletal residence time has both therapeutic and safety implications, as it allows for the possibility of once-weekly dosing and, conversely, raises questions about the long-term effects of bisphosphonate accumulation in bone.
Clinical indications and evidence base
The prevention and treatment of postmenopausal osteoporosis represent the primary and most studied indications for Fosamax therapy. The Fracture Intervention Trial, a landmark randomized controlled study that enrolled over two thousand postmenopausal women with low bone mineral density and existing vertebral fractures, demonstrated that Alendronate reduced the risk of new radiographic vertebral fractures by approximately forty-seven percent, clinical vertebral fractures by approximately forty-five percent, and hip fractures by approximately fifty-one percent over three years of treatment. In the subset of women without existing vertebral fractures, Alendronate reduced the risk of radiographic vertebral fractures by approximately forty-four percent. These results established Fosamax as one of the most effective interventions available for reducing fracture risk in postmenopausal osteoporosis.
The efficacy of Fosamax in the prevention of bone loss in postmenopausal women without established osteoporosis has also been demonstrated in clinical trials. Women in the early postmenopausal period, typically within three to five years of menopause, who received Alendronate showed increases in bone mineral density at the spine and hip, whereas those receiving placebo experienced progressive bone loss. These findings support the use of Fosamax for osteoporosis prevention in postmenopausal women with low bone mass who are at increased risk of progression to osteoporosis, though the decision to initiate therapy in this population should incorporate an assessment of absolute fracture risk using validated risk assessment tools such as the Fracture Risk Assessment Tool.
Glucocorticoid-induced osteoporosis is another important indication for Fosamax therapy, reflecting well-established adverse effects of chronic corticosteroid therapy on bone metabolism. Corticosteroids impair bone formation by promoting osteoblast apoptosis and inhibiting osteoblastogenesis, while also increasing bone resorption through complex mechanisms involving calcium metabolism and the receptor activator of nuclear factor kappa-B ligand pathway. Patients receiving long-term glucocorticoid therapy, typically defined as the equivalent of prednisone 7.5 milligrams daily or more for three months or longer, should be considered for bisphosphonate therapy to prevent bone loss and reduce fracture risk. Clinical trials have demonstrated that Alendronate prevents bone loss and reduces the incidence of vertebral fractures in patients receiving chronic glucocorticoid therapy, supporting its use as a first-line bone-protective agent in this population.
Male osteoporosis is a clinical indication for Fosamax that has been validated through clinical trials. While osteoporosis has traditionally been viewed as a disease of postmenopausal women, it affects a significant number of men, with age-related bone loss, hypogonadism, chronic glucocorticoid therapy, and excessive alcohol consumption representing common contributing factors. Clinical trials have demonstrated that Alendronate increases bone mineral density and reduces the incidence of vertebral fractures in men with osteoporosis, with efficacy comparable to that observed in postmenopausal women. The dosing of Fosamax in men is the same as that recommended for postmenopausal women, and the administration requirements and safety considerations apply equally to both populations.
When researching medication options,
Happy Family Store
offers information about Fosamax and other pharmaceutical products. All decisions regarding the use of prescription medications for osteoporosis should be made under the supervision of a qualified healthcare provider who can perform appropriate evaluation, prescribe therapy when indicated, and monitor treatment response and safety.
Dosing regimens and administration protocols
The dosing of Fosamax has evolved since its introduction, with once-weekly dosing representing the current standard for most patients. The recommended dose for the treatment of postmenopausal osteoporosis is 70 milligrams taken once weekly, while the dose for prevention is 35 milligrams once weekly. The availability of an once-weekly formulation represented a significant advance in convenience and, in many cases, tolerability compared to the original 10-milligram daily dosing regimen. The once-weekly dosing schedule exploits the prolonged skeletal residence time of Alendronate, which allows for adequate suppression of bone resorption with intermittent administration. For patients who prefer daily dosing or for whom the weekly tablet is not suitable, the 5-milligram daily dose for prevention or the 10-milligram daily dose for treatment remain available.
Proper administration of Fosamax is critical to ensuring adequate absorption and minimizing the risk of upper gastrointestinal adverse effects, particularly esophageal irritation. The medication must be taken first thing in the morning, on an empty stomach, with a full glass of plain water, at least thirty minutes before consuming any food, beverages other than water, or other medications. The patient must remain upright, either sitting or standing, for at least thirty minutes after taking Fosamax and should not lie down until after the first food of the day has been consumed. These instructions are designed to ensure that the tablet transits rapidly through the esophagus into the stomach, minimizing the contact time between the medication and the esophageal mucosa, which is susceptible to irritation from bisphosphonates. Failure to adhere to these administration instructions increases the risk of esophagitis, esophageal erosions, and esophageal ulceration.
Adequate calcium and vitamin D intake is essential during Fosamax therapy to support bone mineralization and to prevent the hypocalcemia that can occur when bone resorption is suppressed without adequate mineral substrate for new bone formation. The recommended daily calcium intake for postmenopausal women and older men is approximately 1200 milligrams, achieved through a combination of dietary sources and supplementation. Vitamin D supplementation, typically 800 to 1000 international units daily, ensures adequate calcium absorption and supports bone health. Calcium supplements, if needed, should be taken at a different time of day than Fosamax, as calcium and other divalent cations can chelate Alendronate in the gastrointestinal tract and reduce its absorption. Patients should be assessed for baseline calcium and vitamin D status, and supplementation should be adjusted as needed to achieve optimal levels.
Adverse effects and safety monitoring
Upper gastrointestinal adverse effects represent the most commonly encountered tolerability issue with oral bisphosphonate therapy and include esophagitis, esophageal erosions and ulcers, gastritis, dyspepsia, and abdominal pain. The incidence and severity of these effects can be minimized through strict adherence to the recommended administration instructions, including the upright posture requirement and the use of plain water only for taking the tablet. Patients who develop symptoms suggestive of esophageal irritation, including difficulty or pain with swallowing, retrosternal chest pain, or new or worsening heartburn, should discontinue Fosamax and seek medical evaluation. Esophageal adverse effects are more common in patients with pre-existing esophageal disorders, including achalasia, esophageal stricture, and Barrett’s esophagus, and Fosamax is contraindicated in patients with esophageal abnormalities that delay esophageal emptying.
Musculoskeletal pain, including bone, joint, and muscle pain, has been reported in patients receiving bisphosphonate therapy. This pain is generally mild to moderate in severity and typically resolves with continued treatment or upon discontinuation of the medication. In some cases, the onset of severe musculoskeletal pain has been reported within days to months after initiating bisphosphonate therapy, and while the mechanism is not fully understood, it may relate to the acute-phase response that can occur with potent antiresorptive therapy. Patients experiencing persistent or severe musculoskeletal pain should be evaluated for alternative explanations, and consideration should be given to discontinuing Fosamax if the pain is determined to be drug-related and does not resolve with continued therapy.
Osteonecrosis of the jaw is a rare but serious adverse effect that has been associated with bisphosphonate therapy, particularly in patients receiving high-dose intravenous bisphosphonates for the treatment of malignancy. The risk of osteonecrosis of the jaw with oral bisphosphonate therapy for osteoporosis is lower, estimated at approximately one to ten cases per hundred thousand patient-years of exposure, but the potential severity of this complication warrants awareness and appropriate preventive measures. Risk factors for osteonecrosis of the jaw include invasive dental procedures, including tooth extractions and dental implants, poor oral hygiene, pre-existing dental disease, and concomitant therapy with corticosteroids or antiangiogenic agents. Patients should have a dental examination and any necessary dental procedures completed before initiating Fosamax therapy, and good oral hygiene should be maintained throughout treatment. Invasive dental procedures should be avoided during therapy when possible, and if they are unavoidable, the risks and benefits of temporarily discontinuing Fosamax should be discussed with the treating clinician.
Atypical femoral fractures, characterized by low-energy or spontaneous fractures occurring in the subtrochanteric or diaphyseal region of the femur, have been reported in association with long-term bisphosphonate therapy. These fractures are often preceded by prodromal pain in the thigh or groin, may be bilateral, and display characteristic radiographic features including a transverse or oblique fracture line, lateral cortical thickening, and a medial beak or spike. The proposed mechanism involves the suppression of bone remodeling, which allows microdamage to accumulate in areas of high tensile stress, eventually leading to catastrophic failure of the bone. The absolute risk of atypical femoral fractures is low, estimated at approximately three to fifty cases per hundred thousand patient-years of bisphosphonate exposure, and the risk of typical osteoporotic fractures prevented by bisphosphonate therapy far exceeds the risk of atypical fractures induced by treatment. Nevertheless, patients receiving long-term Fosamax therapy should be questioned about thigh or groin pain, and any such symptoms should be evaluated with radiographic imaging of both femurs.
Contraindications and drug interactions
Several absolute and relative contraindications to Fosamax therapy guide appropriate patient selection and minimize the risk of adverse outcomes. Hypocalcemia, whether symptomatic or asymptomatic, must be corrected before initiating bisphosphonate therapy, as the inhibition of bone resorption reduces calcium efflux from bone and can exacerbate or precipitate hypocalcemia. Patients should have their serum calcium levels measured before starting Fosamax, and vitamin D deficiency, a common cause of hypocalcemia in older adults, should be treated. Severe renal impairment, defined by a creatinine clearance of less than 35 milliliters per minute, is a contraindication to Fosamax therapy, as the drug is eliminated primarily by the kidneys and impaired renal function can lead to drug accumulation and increased toxicity. Patients with milder degrees of renal impairment do not require dose adjustment but should have their renal function monitored periodically during therapy.
Abnormalities of the esophagus that delay esophageal emptying, including achalasia, esophageal stricture, and severe dysmotility, represent contraindications to oral bisphosphonate therapy. The inability to stand or sit upright for at least thirty minutes, whether due to physical disability or other reasons, similarly precludes the safe use of oral bisphosphonates, as the supine position after dosing increases the risk of esophageal contact and injury. For patients with these contraindications, alternative osteoporosis therapies that are not administered orally, such as intravenous zoledronic acid or subcutaneous denosumab, should be considered. Known hypersensitivity to Alendronate or any of the tablet excipients is an absolute contraindication to Fosamax therapy.
Drug interactions with Fosamax are primarily related to interference with drug absorption rather than to pharmacokinetic or pharmacodynamic interactions at the systemic level. Calcium supplements, antacids containing calcium, magnesium, or aluminum, and other oral medications containing divalent cations can form insoluble complexes with Alendronate in the gastrointestinal tract, reducing its absorption. For this reason, these products should be taken at a different time of day than Fosamax, separated by at least thirty minutes from the Alendronate dose. Similarly, food, beverages other than plain water, and mineral water with a high mineral content can interfere with Alendronate absorption and should be avoided during the thirty-minute waiting period after dosing. Nonsteroidal anti-inflammatory drugs, which can independently irritate the gastrointestinal mucosa, may increase the risk of gastrointestinal adverse effects when used concurrently with oral bisphosphonates, and their use should be minimized or avoided when possible in patients receiving Fosamax.
Duration of therapy and treatment holidays
The optimal duration of bisphosphonate therapy has been the subject of considerable investigation and discussion within the osteoporosis community. The prolonged skeletal residence time of Alendronate raises the possibility that continued antiresorptive effects may persist for years after treatment discontinuation, potentially allowing for drug holidays during which patients can take a break from therapy while still benefiting from residual fracture protection. The Fracture Intervention Trial Long-term Extension study, which compared continued Alendronate therapy for ten years versus discontinuation after five years, demonstrated that women who discontinued Alendronate after five years experienced gradual declines in bone mineral density but maintained fracture protection comparable to those who continued therapy for most outcomes. These findings support the concept of a bisphosphonate holiday for lower-risk patients who have completed an initial treatment period.
Current clinical guidelines generally recommend that patients who have completed five years of oral bisphosphonate therapy be reassessed for the ongoing need for treatment. Patients at high risk of fracture, defined by a pre-existing vertebral fracture, hip fracture, or bone mineral density that remains in the osteoporotic range at the total hip, should generally continue therapy, as the benefits of ongoing treatment in fracture reduction outweigh the risks. Patients at moderate risk may be considered for a drug holiday of two to three years, with periodic reassessment of bone mineral density and fracture risk to determine when therapy should be resumed. Patients at low risk, particularly those who initiated therapy for prevention rather than treatment of established osteoporosis, may discontinue therapy with continued monitoring. The decision to initiate a drug holiday, its duration, and the criteria for resuming therapy should be individualized based on each patient’s clinical circumstances and preferences.
During a bisphosphonate holiday, patients should continue adequate calcium and vitamin D intake and should maintain a bone-healthy lifestyle including weight-bearing exercise, smoking cessation, and moderation of alcohol consumption. Bone mineral density should be monitored periodically, typically every one to two years, and a significant decline in bone mineral density or the occurrence of an incident fracture should prompt reconsideration of the need to resume therapy. The development of new clinical risk factors, including the initiation of high-dose glucocorticoid therapy or the diagnosis of a condition associated with accelerated bone loss, may also warrant an earlier return to bisphosphonate treatment. Patients should be counseled that the risk of atypical femoral fractures and osteonecrosis of the jaw, while low, appears to increase with the duration of bisphosphonate exposure, and that the institution of a drug holiday is intended, in part, to mitigate these risks.
Comparison with alternative osteoporosis therapies
The therapeutic landscape for osteoporosis has expanded considerably, offering clinicians and patients multiple treatment options with different mechanisms of action, efficacy profiles, and safety considerations. Among oral bisphosphonates, risedronate and ibandronate represent alternatives to Alendronate. Risedronate has demonstrated efficacy in reducing vertebral and non-vertebral fractures, with clinical trial results comparable to those of Alendronate, and some data suggest a more rapid onset of fracture protection and potentially fewer gastrointestinal side effects with the 35-milligram weekly dose. Ibandronate, available as a 150-milligram monthly oral tablet, offers the convenience of less frequent dosing, though it has not demonstrated significant efficacy in reducing non-vertebral fractures in clinical trials, and its use is generally considered for patients in whom the primary concern is vertebral fracture prevention.
Intravenous bisphosphonates, including zoledronic acid administered annually and ibandronate administered every three months, eliminate the gastrointestinal tolerability issues and adherence challenges associated with oral bisphosphonates. Zoledronic acid has demonstrated efficacy in reducing vertebral, non-vertebral, and hip fractures in postmenopausal osteoporosis and is particularly useful for patients who cannot tolerate oral bisphosphonates, who have difficulty adhering to the oral administration requirements, or who require intravenous therapy for other reasons. The acute-phase reaction, characterized by influenza-like symptoms including fever, myalgia, and arthralgia occurring within the first few days after infusion, is the most common adverse effect of intravenous bisphosphonates and is generally self-limited.
Denosumab, a fully human monoclonal antibody directed against receptor activator of nuclear factor kappa-B ligand, is a newer class of antiresorptive therapy with a mechanism distinct from that of bisphosphonates. By inhibiting RANK ligand, denosumab prevents the formation, function, and survival of osteoclasts, producing potent and sustained suppression of bone resorption. Administered as a subcutaneous injection every six months, denosumab has demonstrated efficacy in reducing vertebral, non-vertebral, and hip fractures comparable to or exceeding that of bisphosphonates. The reversibility of denosumab’s effects upon discontinuation, with rapid loss of accrued bone mineral density and a potential increase in vertebral fracture risk, necessitates careful consideration of treatment continuity and the transition to alternative therapies when denosumab is discontinued. Teriparatide and abaloparatide, anabolic agents that stimulate bone formation rather than inhibiting resorption, offer an alternative therapeutic approach for patients with severe osteoporosis or those who have failed to respond to antiresorptive therapy.
Patient education and adherence support
Successful treatment of osteoporosis with Fosamax depends heavily on patient understanding and adherence to the specific administration requirements. Healthcare providers should take the time to educate patients thoroughly about why the medication must be taken on an empty stomach with plain water only, why the upright posture must be maintained for thirty minutes after dosing, and why the timing of food, beverages, and other medications relative to Fosamax administration is critical for both efficacy and safety. Written instructions, illustrated guides, and demonstration of the proper technique can reinforce verbal counseling and improve adherence. For patients who have difficulty with the oral bisphosphonate regimen despite education and support, alternative therapies that are not subject to the same administration constraints should be considered.
The asymptomatic nature of osteoporosis before a fracture occurs presents challenges for treatment adherence, as patients may not perceive an immediate benefit from therapy to motivate them to continue. Healthcare providers should explain the silent progression of bone loss and the long-term nature of treatment benefit, noting that the reduction in fracture risk achieved by Fosamax is a cumulative effect that requires sustained therapy. The results of bone densitometry, when available, can provide concrete evidence of treatment response and reinforce the importance of continued adherence. Regular follow-up visits, even when brief, provide opportunities to assess adherence, address any barriers to consistent medication use, and reinforce the importance of ongoing therapy. The therapeutic partnership between patient and clinician is essential to realizing the full benefits of osteoporosis treatment in reducing fracture risk and preserving mobility, independence, and quality of life.
The role of fosamax in fracture prevention strategies
The ultimate goal of osteoporosis treatment with Fosamax is the prevention of fragility fractures, the clinical events that cause pain, disability, loss of independence, and increased mortality. The reduction in fracture risk achieved with Alendronate therapy has been documented across multiple fracture types, including vertebral fractures, which are the most common osteoporotic fractures, hip fractures, which carry the highest morbidity and mortality, and non-vertebral fractures including those of the wrist, proximal humerus, and pelvis. The magnitude of fracture risk reduction varies by fracture site, with reductions of approximately forty to fifty percent for vertebral fractures, thirty to fifty percent for hip fractures, and twenty to thirty percent for non-vertebral fractures overall. These reductions translate into clinically meaningful benefits for patients, preserving mobility, reducing the need for hospitalization and long-term care, and maintaining the quality of life that is compromised by fracture-related disability.
Fracture risk assessment is a dynamic process that should be periodically reassessed throughout the course of Fosamax therapy. The initial decision to initiate treatment is typically based on a combination of bone mineral density measurements and clinical risk factors, but the ongoing need for treatment should be informed by the patient’s evolving clinical status, the duration of therapy, and any new information about treatment risks or benefits. Bone mineral density monitoring provides an objective measure of treatment response, with a stable or increasing bone mineral density indicating an adequate pharmacological effect. However, the relationship between bone mineral density changes and fracture risk reduction is not linear, and a substantial portion of the fracture risk reduction achieved with bisphosphonate therapy is attributable to mechanisms beyond increases in bone mineral density, including improvements in bone microarchitecture and reductions in bone turnover markers.
The use of bone turnover markers as an adjunct to bone mineral density monitoring has been explored as a means of assessing the pharmacological response to Fosamax more rapidly than is possible with bone densitometry. Markers of bone resorption, including serum C-telopeptide and urinary N-telopeptide, decline within weeks of initiating bisphosphonate therapy, reaching a nadir within three to six months. A significant reduction in bone turnover markers provides early evidence of a pharmacological response and can reinforce treatment adherence. However, the clinical utility of routine bone turnover marker monitoring in individual patients remains debated, as the relationship between the magnitude of marker reduction and the degree of fracture risk reduction is not sufficiently precise to guide clinical decision-making. The measurement of bone turnover markers is most useful in cases where adherence or absorption is questioned, where a lack of biochemical response may indicate the need to investigate the cause of treatment failure.
Managing long-term fosamax therapy and transitions of care
As patients continue Fosamax therapy over years, the cumulative benefits and risks of treatment must be weighed periodically, and the decision to continue, discontinue, or modify therapy should be revisited at least annually. The risk of atypical femoral fractures and osteonecrosis of the jaw, while low in absolute terms, increases with the duration of bisphosphonate exposure, and the incremental fracture risk reduction achieved with continued therapy beyond five years becomes less certain, particularly for patients who are no longer at high risk of fracture. These considerations have led to the concept of the bisphosphonate holiday, a planned interruption of therapy during which the residual skeletal effects of the bisphosphonate provide ongoing fracture protection while the risks associated with continued therapy are minimized. The appropriate timing and duration of drug holidays remain areas of active investigation and clinical judgment, with current guidelines generally recommending consideration of a holiday after five years of therapy in patients at moderate risk and continuation of therapy in patients at high risk.
The transition from Fosamax to alternative osteoporosis therapies may be indicated in several clinical scenarios, including treatment failure defined by an incident fracture or significant bone loss despite adequate adherence, the development of contraindications to oral bisphosphonate therapy, or the desire for greater convenience or efficacy. The transition to intravenous zoledronic acid eliminates the gastrointestinal tolerability issues and adherence challenges of oral therapy while providing annual dosing that may be particularly suitable for patients with polypharmacy or cognitive impairment. The transition to denosumab requires careful planning, as the rapid offset of denosumab’s effects upon discontinuation necessitates either continued therapy indefinitely or a planned transition to a bisphosphonate to prevent the rebound bone loss and increased vertebral fracture risk that can occur with denosumab cessation. Anabolic therapy with teriparatide or abaloparatide may be considered for patients with severe osteoporosis who have sustained fractures despite antiresorptive therapy, as these agents stimulate bone formation through mechanisms distinct from the antiresorptive action of bisphosphonates.